Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines
Thomas, KR, Bangen, KJ, Edmonds, EC, Weigand, AJ, Walker, KS, Bondi, MW, Galasko, DR and Alzheimer's Dis Neuroimaging, I
2021; Journal Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring; vol. 13; no. 1; pp. 11;
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Royse, SK, Minhas, DS, Lopresti, BJ, Murphy, A, Ward, T, Koeppe, RA, Bullich, S, DeSanti, S, Jagust, WJ and Landau, SM
2021; Journal Alzheimer's Research & Therapy; vol. 13; no. 1; pp. 10-Jan;
Comparing data-driven and hypothesis-driven MRI-based predictors of cognitive impairment in individuals from the Atherosclerosis Risk in Communities (ARIC) study
Casanova, R, Hsu, FC, Barnard, RT, Anderson, AM, Talluri, R, Whitlow, CT, Hughes, TM, Griswold, M, Hayden, KM, Gottesman, RF, Wagenknecht, LE and Alzheimer's Dis Neuroimaging, I
2021; Journal Alzheimers & Dementia; vol. 11;
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
Hong, SJ, Dobricic, V, Ohlei, O, Bos, I, Vos, SJB, Prokopenko, D, Tijms, BM, Andreasson, U, Blennow, K, Vandenberghe, R, Gabel, S, Scheltens, P, Teunissen, CE, Engelborghs, S, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Lleo, A, Alcolea, D, Popp, J, Clark, C, Peyratout, G, Martinez-Lage, P, Tainta, M, Dobson, RJB, Legido-Quigley, C, Sleegers, K, Van Broeckhoven, C, Tanzi, RE, ten Kate, M, Wittig, M, Franke, A, Lill, CM, Barkhof, F, Lovestone, S, Streffer, J, Zetterberg, H, Visser, PJ, Bertram, L and Neuroimaging, I
2021; Journal Alzheimers & Dementia;